Table 2: Comparison of baseline features between study population and patients lost at follow-up.
|
Long-term follow-up study 52 patients (%) |
Patients lost at long-term follow-up 48 patients (%) |
Age |
49 years (max 76, min 19) |
57 years (max 76, min 19) |
Sex (M:F) |
2.1 (35/17) |
1.3 (27/21) |
Histology (HGG/LGG) |
3.7 (41/11) |
3.6 (36/10) |
Tumor location |
||
Frontal |
36 (69.2%) |
24 (50.0%) |
Temporal |
19 (36.5%) |
18 (38.5%) |
Parietal |
13 (25.0%) |
14 (29.2%) |
Occipital |
5 (9.6%) |
5 (10.4%) |
Insula |
6 (11.5%) |
2 (4.2%) |
Other |
6 (11.5%) |
6 (12.5%) |
Multilobar |
25 (48.1%) |
12 (25.0%) |
Seizure type |
||
Motor |
15 (28.8%) |
16 (33.3%) |
Somato-sensory |
8 (15.4%) |
3 (6.3%) |
Loss of consciousness |
10 (19.2%) |
10 (20.8%) |
Other |
8 (15.4%) |
4 (8.3%) |
Tonic-Clonic |
20 (38.5%) |
25 (52.1%) |
Frequency |
||
Low (< 1/Month) |
31 (59.6%) |
37 (71.2%) |
High (> 1/Month) |
21 (40.4%) |
11 (22.9%) |
Weekly |
8 (15.4%) |
0 |
Daily |
9 (17.3%) |
1 (2.0%) |
Status epilepticus |
4 (7.7%) |
8 (16.7%) |
Surgery
|
||
Radical surgery |
13 (25.0%) |
25 (52.1%) |
Post-surgery residue |
33 (63.5%) |
20 (41.6%) |
General prognosis |
||
Dead |
23 (44.2%) |
21 (43.8%) |